For the study, researchers analyzed the average cost for 24 patented, injectable cancer treatments approved between 1996 and 2012 using average sales prices published by CMS.
The average price increase for all drugs was 25 percent over eight years. When researchers accounted for inflation, the average price increase was 18 percent.
Increased competition or newly approved uses for the cancer drugs did not affect annual price change rates.
“In a normally functioning market, competition should decrease prices,” study author Daniel Goldstein, MD, an adjunct assistant professor at Atlanta-based Emory University, told Reuters. “But we saw competition actually seems to drive prices up. We don’t specifically have evidence that the companies are talking to each other and raising their prices simultaneously, but one could consider that as a possible conclusion from these findings.”
More articles on supply chain:
UnitedHealth not concerned by possibility of Amazon entering drug business
FDA greenlights OptiScan’s bedside glucose monitoring system
The problem with eye drops — and why drug companies won’t fix it
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
